Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 6/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045443 | 0.89 | MEN1 (0.45) | KMT2ALMNAMEN1RAB9ABACE1 | |
| SCHEMBL7186569 | 0.88 | MEN1 (0.40) | KMT2AMEN1RAB9ABACE1HPGD | |
| SCHEMBL7042908 | 0.87 | DAGLA (0.47) | KMT2AMEN1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7049306 | 0.78 | DAGLA (0.44) | KMT2ALMNAMEN1RAB9AHPGD | |
| SCHEMBL7045308 | 0.76 | CTSS (0.49) | KMT2ALMNAMEN1RAB9ATP53 | |
| SCHEMBL6465748 | 0.76 | LMNA (0.40) | KMT2ALMNARAB9ATP53SMN1; SMN2 | |
| SCHEMBL7047959 | 0.76 | MEN1 (0.44) | KMT2ALMNAMEN1RAB9AHPGD | |
| SCHEMBL6465745 | 0.75 | KMT2A (0.43) | KMT2ALMNAMEN1RAB9ATP53 | |
| SCHEMBL6464160 | 0.74 | LMNA (0.39) | KMT2ALMNAMEN1RAB9ATP53 | |
| SCHEMBL7045311 | 0.73 | KMT2A (0.42) | KMT2ALMNAMEN1RAB9ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | KMT2A 3705/4885LMNA 1755/4885MEN1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.